Systemic absorption of progesterone from Progest cream in postmenopausal women

Cooper, Alexandra; Spencer, Christopher; Whitehead, M. I.; Ross, David J.; Barnard, Geoff; Collins, W. P.

doi:10.1016/s0140-6736(05)79323-5

Cited by 61 publications

(45 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It contains 200 mg of progesterone per ounce. [98][99][100][101] Percutaneous progesterone absorption is virtually zero when Progest cream is applied. A typical dose is 1 ⁄2 to 1 teaspoon applied topically daily.…”

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

“…A randomized, double-blind, placebocontrolled, crossover study was conducted to determine the absorption of Progest cream in postmenopausal women. 98 Pregnanediol-3-␣-glucuronide, as well as plasma progesterone levels, were measured. Oral micronized progesterone resulted in serum concentrations of 9.5 nmol/L versus Progest at 2.9 nmol/L (range 0.7-15.00).…”

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

“…100 Furthermore, the transcutaneous absorption is extremely variable. 98 According to John Lee, MD, normal salivary progesterone concentrations range from 1.0 to 1.6 nmol/L (0.3-0.5 ng/mL) and can usually be obtained with topical doses of 15 mg per day. 101 However, there is not a linear relationship between the plasma and salivary progesterone concentrations because the salivary concentrations represent the "free, unbound hormone."…”

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

“…Normal serum concentrations range from 6 to 64 nmol/L and are not achieved with Progest. 27,98,101 A study examined the cardiac effects of transvaginal progesterone gel versus MPA as measured by ST segment depression, heart rate, and systolic blood pressure during exercise. 102 All 18 participants received E 2 2 mg per day.…”

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

See 3 more Smart Citations

Bioidentical hormone therapy: a review

Boothby¹,

Doering²,

Kipersztok³

2004

Menopause

103

View full text Add to dashboard Cite

Objective: The terms "natural" or "bioidentical" hormone therapy (NHT) are used to describe hormone treatment with individually compounded recipes of certain steroids in various dosage forms, including dehydroepiandrosterone, pregnenolone, testosterone, progesterone, estrone, estradiol, and estriol. Based on the results of a person's salivary hormone levels, the final composition of the compounded dosage form is individualized to that specific person. Proponents claim that NHT is better tolerated than manufactured products. This paper is intended to review the concept of NHT and to determine whether there is sufficient scientific evidence to support its use.Design: A literature search was performed in Medline using the following MeSH terms and key words: drug combinations; progestational hormones; hormone replacement therapy; endometrium; estrogen replacement therapy; climacteric; menopause; estradiol; estrogens; progesterone; drug monitoring; and drug compounding. Current Contents, International Pharmaceutical Abstracts, Cochrane Database of Systematic Reviews, Lexis Nexis, Google, Medscape, MD Consult, and clinicaltrials.gov were searched with key words.Results: There are a few observational studies and clinical trials comparing conventional hormone therapy with bioidentical hormone therapy. Studies generally lacked adequate study design, including small sample sizes and comparison of inequivalent doses, to prove safety and efficacy. Little evidence was found to support individualized hormone dosing based upon saliva hormone concentrations.Conclusion: Evidence suggests that, although individualized hormonal products may decrease some symptoms of menopause, it seems they have no proven advantage over conventional hormone therapies and their use is not supported by evidence regarding pharmacokinetics, safety, and efficacy.

show abstract

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

Section: Topical Versus Oral Route Of Administrationmentioning

confidence: 99%

See 2 more Smart Citations

Bioidentical hormone therapy: a review

Boothby¹,

Doering²,

Kipersztok³

2004

Menopause

103

View full text Add to dashboard Cite

show abstract

“…Lee claimed improvement in bone density in postmenopausal women over three years with transdermal progesterone cream (Lee 1998). Cooper et al (1998) performed a randomised, double-blind, placebo-controlled cross-over study to evaluate the absorption, metabolism and urinary excretion of progesterone administered transdermally. Serum levels achieved were inadequate for endometrial protection.…”

Section: Endometrial Cancermentioning

confidence: 99%

Postmenopausal hormone therapy: from monkey glands to transdermal patches

Davis

Dinatale²,

Rivera-Woll³

et al. 2005

Journal of Endocrinology

View full text Add to dashboard Cite

The climacteric is not a condition of the modern age, although with increased life expectancy over the centuries, more women will experience this physiological transition. As women are living longer there is a greater expectation that good health will be maintained through to the late decade. Thus the potential long-term adverse health consequences of using hormonal therapies (HTs) to alleviate menopausal symptoms are of considerable concern for women and medical practitioners. This concern is often the basis for a decision whether or not to use HT.We have reviewed the history of knowledge of the menopause and the development of HT for the treatment of climacteric complaints. We have also summarised the current evidence for specific benefits and risks of HT. Data indicate that postmenopausal HT is appropriate for the management of vasomotor symptoms, but that HT should not be prescribed for the prevention of cardiovascular disease or dementia. HT does prevent bone loss and osteoporotic fracture; however, use for this purpose remains controversial. The risk of breast cancer with HT varies according to the preparation used, such that oestrogen without concurrent progestin appears to convey little, or possibly even no significant breast cancer risk. There is insufficient information regarding the long-term use of non-oral HT, low-dose HT or novel compounds such as tibolone or the selective oestrogen receptor modulators with respect to breast cancer and cardiovascular risk for specific recommendations to be made.

show abstract